Alzheimer’s & Dementia

Filter Your Results




Positive Results in Phase 2 Trial of BAN2401 for Treatment of Persons With Alzheimer’s Disease

Friday, July 27, 2018—Detailed results of a phase 2 study (NCT01767311) of BAN2401 (Eisai, Woodcliff Lake, NJ and Biogen, Cambridge, MA) were presented at the Alzheimer's Association Internatio…

Phase 2/3 Clinical Trial of Trigriluzole for Alzheimer's Disease Initiated

Thursday, July 26, 2018—A Phase 2/3 clinical trial of trigriluzole (BHV-4157; Biohaven, Cambridge, MA for treatment of patients with mild-to-moderate Alzheimer's disease (AD) has been initiated i…

Crenezumab and Gantenerumab In Phase 3 Trials for Treating Persons with Alzheimer’s Disease

Thursday, July 26, 2018—Crenezumab and Gantenerumab are 2 monoclonal antibodies directed against amyloid-ß (Aß) soluble and oligomeric forms. Crenezumab more specifically targets oli…

Gut Bacteria and Lipid Metabolism May Influence Alzheimer’s Disease and Dementia

Wednesday, July 25, 2018—Several studies at the Alzheimer’s Association International Conference (AAIC) 2018 showed that lipid, cholesterol, and bile acid metabolism correlate with biomarkers fo…

Having Children May Be Associated With Reduced Risk of Dementia and Other Sex-Specific Differences in Dementia

Tuesday, July 24, 2018—While it has long been known that AD is more prevalent in women than men (3:2) in the US, the reasons for this are not fully understood; theories include women's longer li…

Alzheimer’s Association Releases First Clinical Evaluation Guideline

Monday, July 23, 2018—New evidence-based consensus guidelines for the evaluation of cognitive-behavioral symptoms of Alzheimer's disease (AD) and other dementias have been released and strongly…

Meningeal Enhancement Seen on Workup for Memory Loss

Nima Khosravani, MS; Anamaria Shanley, MSN, ARNP-BC; and Ira J. Goodman, MD

July/August 2018—Inflammation in the context of memory loss reminds us of the importance of checking opening pressure on lumbar puncture.

Investigational Tau Modifier Receives Orphan Drug Status for Progressive Supranuclear Palsy

Wednesday, July 18, 2018—The Food and Drug Administration (FDA) has granted an orphan drug designation to ASN120290 (Asceneuron SA, Lausanne, Switzerland) for the treatment of progressive supranuclear…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.